Product Name

Molecular Formula

Sequence

PEG-PQ

C₅₀H₇₆N₁₆O₁₅

H-GGGPQGIWGQGK-OH

ACT1

C₁₅₀H₂₃₈N₄₈O₃₄

H-RQPKIWFPNRRKPWKKRPRPDDLEI-OH

WT1C

C₄₂H₇₃N₉O₁₁

H-ALLPAVPSL-OH

EBV LMP2

C₃₉H₇₁N₉O₁₁S₂

H-CLGGLLTMV-OH

KHS-Cnd

C₁₂₂H₂₀₄N₃₂O₂₅

H-WFGKLYRGITKVVKKVKGLLKG-OH

Human FOXP2(703-715)

C₆₆H₁₀₆N₁₆O₂₉

H-REIEEEPLSEDLE-OH

NLS

C₃₂H₆₅N₁₉O₇

H-KRRRRG-OH

Tyrp1

C₄₂H₆₄N₁₀O₁₅S

H-TAPDNLGYM-OH

HPV E7 (82-90)/LV9

C₄₂H₇₇N₉O₁₁S

H-LLMGTLGIV-OH

HPV16 E7(7–15)

C₅₁H₇₉N₁₁O₁₆S

H-TLHEYMLDL-OH

MAGE-C1 (1083-1091)/p1083

C₅₀H₈₄N₁₀O₁₂S

H-KVVEFLAML-OH

PEG-PQ

C₄₈H₇₃N₁₅O₁₄

H-GGGPQGIWGQK-OH

CP05

C₅₆H₉₉N₂₁O₁₈S₂

H-CRHSQMTVTSRL-OH

GLSNLTHVL

C₄₂H₇₂N₁₂O₁₃

H-GLSNLTHVL-OH

MAGE-A3 - HLA-A*0201

C₅₁H₈₂N₁₂O₁₂

H-KVAELVHFL-OH

Mr-3

C₇₂H₁₁₉N₂₁O₂₆

H-NVIQAPAQSVAPPNTST-OH

MART-1 (HLA-A*0201)

C₄₅H₈₀N₁₀O₁₄

H-ELAGIGILTV-OH

TDIF/CLE41

C₅₃H₈₂N₁₆O₁₉

H-HEVPSGPNPISN-OH

K2(SL)6K2

C₇₈H₁₄₇N₂₁O₂₂

H-KKSLSLSLSLSLSLKK-NH2

MAGE-A4(286-294)

C₄₉H₈₇N₁₅O₁₂

H-KVLEHVVRV-OH

NY-ESO-1 - HLA-A*0201

C₄₉H₇₉N₁₁O₁₃S₂

H-SLLMWITQC-OH

Cysteine Peptide

C₃₂H₅₀N₁₀O₉S

Ac-RFAACAA-OH

Pentapeptide-3

C₂₁H₃₇N₉O₅

H-GPRPA-NH2

Ruxotemitide (LTX 315)

C₇₈H₁₀₆N₁₈O₉

KKWWKKW-Dip-K-NH2

galectin-3 peptide

C₃₉H₆₃N₁₁O₁₁

H-IALDFQR-OH

P5

C₄₁H₇₁N₁₃O₁₅

H-LQLQAEER-OH

tau peptide

C₅₀H₇₇N₁₃O₁₇

H-TDHGAEIVYK-OH

TIMP-1

C₅₃H₈₄N₁₆O₁₈

H-GFQALGDAADIR-OH

CK-19

C₄₁H₅₉N₁₁O₉

H-FGPGVAFR-OH

EBV BMLF1

C₄₀H₇₃N₉O₁₁S₂

H-GLCTLVAML-OH

CEA 27-35

C₆₁H₇₇N₁₃O₁₃

H-HLFGYSWYK-OH

M2pep

C₈₃H₁₀₁N₁₇O₂₀

H-YEQDPWGVKWWY-OH

PSP1

C₅₀H₆₇N₉O₁₅S₂

H-CLSYYPSYC-OH

AT1002

C₃₂H₅₃N₉O₇S

H-FCIGRL-OH

Terlipressin

C₅₂H₇₄N₁₆O₁₅S₂

H-GGGCYFQNCPKG-NH2, disulfide bridge: Cys4-Cys9

human GHRH(1-44), amide

C₂₁₅H₃₅₈N₇₂O₆₆S

H-YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH2

Retatrutide (LY3437943), 99% purity

C₂₂₁H₃₄₂N₄₆O₆₈

JH8194

C₉₈H₁₅₂N₃₂O₁₇S

H-KRLFRRWQWRMKKY-OH

αS1-casein

C₆₀H₉₄N₁₄O₁₆

H-YLGYLEQLLR-OH

Hexarelin